BMJ, August 20, 2021: The FDA is being criticized for not holding an advisory committee meeting to discuss Pfizer’s application for full approval of its covid-19 vaccine. Will it undermine public confidence?
Read More »We’re In The News
As a respected nonprofit health research center, our views are often quoted in the media, including newspapers, magazines, TV, radio, and websites. We also write articles and blogs for a number of different and highly respected newspapers, magazines, and popular websites, and we are published in prestigious medical journals and health policy publications. We frequently express our policy views in letters to government officials and public comments to federal agencies and we sometimes release statements or press releases on newsworthy issues.
Please e-mail info@center4research.org or call 202-223-4000 with your inquiries. We can assist you with scheduling interviews with the NCHR President, Dr. Diana Zuckerman, and other experts on our staff.
Biden yet to nominate new FDA chief even as delta surges
The Hill, August 8, 2021: FDA news a new focus on public health that protects patient safety and ensures strong scientific evidence. We explain to The Hill that making the right choice is as important as making a decision soon.
Read More »7 things to know about bad COVID-19 tests
CBS 5, July 29, 2021: This CBS 5 investigation about FDA emergency use authorizations (EUAs) for COVID tests will shock you! Thanks to Kris Pickel, you can find out why so many COVID tests and antibody tests were not accurate and how many we still aren’t sure of.
Read More »Beleaguered FDA in talks for drug-company funding
Marketwatch, July 13, 2021: Fees paid by drug companies make up half of the FDA’s revenue. Dr. Diana Zuckerman explains how these fees often influence FDA decisions and sacrifice patient safety.
Read More »Drug Prices Are One Focus of Biden’s Push to Boost Competition
Wall Street Journal, July 9, 2021: Drug prices in the US are extremely high with both sides of the aisle advocating for Medicare to be able to negotiate drug prices. Dr. Diana Zuckerman spoke with the WSJ about how President Biden plans to lower drug prices.
Read More »